Copyright
©The Author(s) 2015.
World J Obstet Gynecol. Feb 10, 2015; 4(1): 16-23
Published online Feb 10, 2015. doi: 10.5317/wjog.v4.i1.16
Published online Feb 10, 2015. doi: 10.5317/wjog.v4.i1.16
Table 1 Correlation of hepatoma-derived growth factor expression levels with clinicopathological factors in uterine cervical cancer patients n (%)
Factor | Category | No. ofpatients | HDGF expression | P value | ||
Level 0 | Level 1 | Level 2 | ||||
n = 88 | n = 19 | n = 11 | n = 58 | |||
Age, yr | 51.6 ± 13.8 | 46.7 ± 15.5 | 55.6 ± 12.1 | 52.4 ± 13.2 | 0.17 | |
Histological differentiation | 1: Keratinized SQ | 29 | 2 (7) | 2 (7) | 25 (86) | 0.037 |
2: Nonkeratinized SQ | 58 | 17 (29) | 9 (16) | 32 (55) | ||
3: Adenosquamous carcinoma | 1 | 0 (0) | 0 (0) | 1 (100) | ||
Lymphatic permeation | 1: Absent | 53 | 18 (34) | 6 (11) | 29 (55) | 0.0006 |
2: Present | 35 | 1 (3) | 5 (14) | 29 (83) | ||
Vascular permeation | 1: Absent | 65 | 18 (28) | 6 (9) | 41 (63) | 0.019 |
2: Present | 23 | 1 (4) | 5 (22) | 17 (74) | ||
Depth of invasion (pT) | 1: T1 | 41 | 15 (37) | 6 (15) | 20 (49) | 0.028 |
2: T2 | 43 | 4 (9) | 4 (9) | 35 (81) | ||
3: T3 | 3 | 0 (0) | 1 (33) | 2 (67) | ||
4: T4 | 1 | 0 (0) | 0 (0) | 1 (100) | ||
Lymph node metastasis (pN) | 1: Absent | 64 | 12 (19) | 9 (14) | 36 (56) | 0.0004 |
2: Present | 24 | 0 (0) | 2 (8) | 22 (92) | ||
Stage | 1: I | 43 | 15 (35) | 7 (16) | 21 (49) | 0.014 |
2: II | 36 | 4 (11) | 4 (11) | 28 (88) | ||
3: III | 5 | 0 (0) | 0 (0) | 5 (100) | ||
4: IV | 4 | 0 (0) | 0 (0) | 4 (100) | ||
Types of surgery | 1: Conization | 2 | 2 (100) | 0 (0) | 0 (0) | 0.0001 |
2: Total hysterectomy | 7 | 7 (100) | 0 (0) | 0 (0) | ||
3: Modified radical hysterectomy | 7 | 4 (57) | 0 (0) | 3 (43) | ||
4: Radical hysterectomy | 72 | 6 (8) | 11 (15) | 55 (76) | ||
Salpingo-oophorectomy | 1: Not performed | 17 | 12 (71) | 2 (12) | 3 (18) | 0.0001 |
2: Performed | 71 | 7 (10) | 9 (13) | 55 (77) | ||
Pelvic lymph node dissection | 1: Not performed | 71 | 14 (20) | 9 (13) | 48 (68) | 0.7 |
2: Performed | 17 | 5 (29) | 2 (12) | 10 (59) | ||
Adjuvant/neoadjuvantchemotherapy | 1: Not performed | 53 | 16 (30) | 5 (9) | 32 (60) | 0.03 |
2: Performed | 35 | 3 (9) | 6 (17) | 26 (74) | ||
Adjuvant radiotherapy | 1: Not performed | 52 | 16 (31) | 9 (17) | 27 (52) | 0.003 |
2: Performed | 36 | 3 (8) | 2 (6) | 31 (86) |
- Citation: Song M, Tomoeda M, Jin YF, Kubo C, Yoshizawa H, Kitamura M, Nagata S, Ohta Y, Kamiura S, Nakamura H, Tomita Y. Hepatoma-derived growth factor expression as a prognostic marker in cervical cancer. World J Obstet Gynecol 2015; 4(1): 16-23
- URL: https://www.wjgnet.com/2218-6220/full/v4/i1/16.htm
- DOI: https://dx.doi.org/10.5317/wjog.v4.i1.16